Moderna plans development programs for 3 new mRNA vaccines
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) said it is expanding its mRNA pipeline with three new development programs.
The programs are for herpes simplex virus (HSV) vaccine candidate mRNA-1608; varicella-zoster virus (VSV) vaccine candidate mRNA-1468 to reduce the rate of shingles; and a new checkpoint cancer vaccine candidate (mRNA-4359).
The company said HSV and VZV are latent viruses that remain in the body for life after infection and can lead to life-long medical conditions. Moderna (MRNA) now has five vaccine candidates against latent viruses in development, including against cytomegalovirus (CMV), Epstein-Barr virus (EBV), Human immunodeficiency virus (HIV), HSV and VZV.
In the cancer vaccine program, the company is planning to explore initial indications for advanced or metastatic cutaneous melanoma and non-small cell lung carcinoma.
MRNA +0.1% premarket to $146.50